Abstract
Introduction:
Type 2 diabetes is one of the major public health concerns in both developing and developed countries. It has become epidemic in a number of countries, particularly in newly industrialised nations. The direct and indirect social and economic costs of treating diabetes and its complications have the potential to cripple the countries' healthcare budgets. In recent times, a new dimension has been added with the increasing appearance of type 2 diabetes in adolescents and even children. Good glycemic control can delay the progression of microvascular or macrovascular complication with in type 2 diabetes mellitus (T2DM) patients. To date, the association between antidiabetic agents and glycemic control in this patient is not well established.
Like many other developing countries, Bangladesh has a major problem of rapid urbanization. Dietary habit, life style modification also changed with urbanization. Any country that experienced to urbanization and industrialization also witnessed with a change of disease pattern from infectious to non-communicable and chronic diseases. Changing in life styles, eating habits, sedentary life, increased use of tobacco and deteriorating environmental conditions are likely to develop non-communicable diseases. At the same time non-communicable diseases and metabolic disorders linked with diabetes (DM), hypertension (HTN) and coronary heart diseases (CHD) are increasing. At present it is estimated that about 7.1 million cases of diabetes in Bangladesh in 2015 and latest data suggested that prevalence of diabetes in adult (20-79 years) is 7.4%. 1 Type 2 Diabetes is defined as chronic hyperglycemia resulting from either decreased insulin secretion, impaired insulin action or both in the absence of autoimmune destruction of the pancreatic beta cell. Type 2 diabetes is now recognized as a major chronic public health problem throughout the world. It affects large number of people of wide range of ethnic and economic levels in both developed and developing countries. 2 Diabetes mellitus can lead to diabetes specific complications and end organ damage which can be prevented or delayed by strict glycemic control and thereby reduce morbidity and mortality among these patients. In a major proportion of patients, oral anti-diabetic drugs are used for glycemic control early in disease course and are effective in many cases to reach the therapeutic targets. Summaries of previous studies of oral antidiabetic drugs (OADs) suggest that they reduce A1C levels by 0.5-1.25%. 3 These oral medications are easy to take and often cost effective in comparison with injectable medications.
Essential components of the treatment for diabetes include diabetes self-management education and support, lifestyle interventions, and goal setting and glycemic management. Each class of oral agents works by a different mechanism and they may be combined to achieve optimal glucose control. The obvious exceptions are sulfonylureas and non-sulfonylurea insulin secretagogues, which should not be combined. 4 Typically, patients with type 2 diabetes are started on metformin, with a second agent or third agent added as needed. In general, the addition of an oral agent will reduce HbA1c by an additional 1.0%. Tablets combining two classes of oral agents are now available.
People with type 2 diabetes often have lifestyles (eating and physical activity habits) which contribute to their problem. Begin oral glucose lowering medications when lifestyle interventions alone are unable to maintain blood glucose control at target levels. First-line therapy begin with metformin unless there is evidence of renal impairment or other contraindication. 5 Other options include a sulfonylurea (or glinide) for rapid response where glucose levels are high, or a-gIucosidase inhibitors in some populations; these agents can also be used initially where metformin cannot. In some circumstances dual therapy may be indicated initially if it is considered unlikely that single agent therapy will achieve glucose targets.
There are several groups of oral medication available, currently five classes of OAD agents commonly used: Alpha glucosidase inhibitors (AGIs), Biguanides, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Insulin Secretagogues -SUs, Non-SUs or Meglitinides and Thiazolidinediones (TZDs). AGIs primarily lower postprandial glucose without causing hypoglycaemia. They are less effective in lowering glycaemia than metformin or SU, reducing HbA1c by 0.5-0.8%. Metformin does not stimulate insulin secretion, and lowers blood glucose by decreasing hepatic glucose production. Metformin monotherapy is usually not accompanied by hypoglycaemia. It can lower plasma glucose by up to 20% as first line drug treatment especially in overweight/obese patients. Metformin monotherapy will lower HbA1c by about 1.5%. 6 Dipeptidyl peptidase-4 (DPP-4) Inhibitor (Sitagliptin) lowers HbA1c by 0.5 -0.8%, its efficacy improves when used at higher HbA1c baselines. Thiazolidinediones are peroxisome proliferator-activated receptor-gamma agonists and act primarily by increasing insulin sensitivity of muscle, adipose tissue and liver to endogenous and exogenous insulin (insulin sensitizers).
Reaching Glycaemic Targets achieved by Self blood glucose monitoring (SBGM) routinely. Monitoring provides information on the effects of therapy, diet and physical activity. Those on OAD agents or diet need to check fasting and 2-hour PPG levels. HbA1c should be measured approximately every 3 to 6 months to ensure that glycaemic targets are being met. This reflects overall glucose control over a 3 month period with recommended target level of 6.5%. To achieve a HbA1c <6.5%, aim for FPG or pre-prandial plasma glucose targets of 4.4 to 6.1 mmol/L and 2-hour PPG targets of 4.4 to 8.0 mmol/L. 6 HbA1c is the most commonly accepted measurement of long-term glycemic control. Current recommendations are that HbA1c be checked at least every 6 months 4 if the patient is well controlled (HbA1c d" 7%) and on a stable oral anti-hypoglycemic regimen, otherwise every 3 months. Targets for therapy have been evaluated in clinical trials. Two trials have achieved A1c levels slightly greater than 7%. Neither showed reduction in end-stage complications in the time frame of the trials (e.g., visual loss, renal failure amputation). However, early and intermediate microvascular complications were reduced, and longerterm follow-up of one study showed that benefits did begin to accrue by 15-20 years. This suggests that a target A1c of 7% to 7.5% is reasonable in those with life expectancies in this range or longer. 4 Glycosylated hemoglobin assays provide an accurate indication of long-term glycemic control. Glycated hemoglobin is formed by the continuous non-enzymatic glycosylation of hemoglobin throughout the lifespan of an erythrocyte. The A1c assay yields an accurate measure of time-averaged blood glucose during the previous six to eight weeks. Clinically, it can assist in determining duration and severity of hyperglycemia and can help guide treatment. Eating, physical activity or acute metabolic stress does not influence the A1c test. The test can be done at any time of day and does not require fasting. 7 Appropriate medication management targeting glycemic control, hypertension, and lipid management is important for reducing morbidity and mortality, and improving long-term quality of life for patients diagnosed with type 2 diabetes mellitus (T2DM). Lifestyle changes such as nutrition therapy, weight loss, increased exercise, and appropriate education and self-management strategies are pivotal to improved outcomes. Inadequate access to care for chronic disease management as well as the cost of medication can contribute to poor control of T2DM and associated cardiovascular risk factors. 7
Methodology:
This quasi experimental Phase IV clinical trial was conducted amongst 600 patients of type 2 DM over a period of 24 months. Samples were selected by quasi experimental type. Sociodemographic variables were age, sex, economic status, educational level, etc. Clinical variables were glycemic status: HbA1C, FBG, 2HABF, Oral anti-diabetic agents. Informed written consent was obtained accordingly. The trial was done according to ICH-GCP and followed the declaration of Helsinki.The patients allocation was semi purposive and not randomized. The drugs which were prescribed was sulfonylureas (S), Biguanides (B) (Metformin) and DPP4 inhibitors(D) (Vildagliptin and Sitagliptin). There was no concealment of allocation and sequential allocation by S, B and D groups. The combination was done with Vildagliptin and metformain(V+M) and sitagliptin and metformin(S+M). So the allocation was 4 cards with one S, One B, One with S+M and one with V+M Primary efficacy was seen of glycaemic control and secondary efficacy was to see the achievement of target glucose. The safety issue was seen with primarily see the number of hypoglycaemic episodes and secondary to see the number of death. (Table II) . 
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Sulphonylureas Meƞormin DPP4 Combined therapy All findings were evaluated in all groups of patients. Present study shows that, for good glycemic control, all three results (FBS, 2H ABF and HbA1c) were within targeted level in majority patients of DPP4 Inhibitor combination group. Although FBS was best result in metformin. About 51.9% of SUs group achieved the glycemic control targets level. In case of metformin group it was in 59.8% of patients, and in combined therapy 67.1% patients shows good glycemic target.
So DPP4 Inhibitor combination is better medication than other to maintain good glycemic status in type 2 DM patient, due to maximum number of patients reached all three components of result within target range. The p-value is 0.023685. The result is significant at p< .05. (Figure-3) .
Discussion:
In this quasi experimental Phase IV Clinical trial we investigated 600 individuals type 2 DM both male and female > 20 years of age. For estimating the glycemic status of diabetes we evaluated fasting blood glucose (FBG), 2-hr post glucose test and HbA1c for selected subjects. We also measured some important sociodemographic and socio-economic information following a pre-tested structured case record form. For diagnosis and defining the diabetes state in our study population we used revised WHO criteria. In this study Maximum number of patients (38.5%) was between 31-40 years age group with mean age 37.8±9.5 years.
Male to female ratio was 1.3:1.
Findings are correlates with the results of similar studies at home and abroad, e.g a cross-sectional study in outpatients medicine department 8 reported that the mean ages (in years) of the male and female diabetic patients were 51.5±1.51 and 50.4±1.46. A study in Bangladesh reported that among study subjects 731 were male, 824 were female, most of the population were young with a mean age 33 years, and about 78 percent were in age category between 20-40 years 2 . Another study in Bangladesh by Akter S; et al. reported that diabetes and prediabetes are highly prevalent among individuals aged 35 years or more in Bangladesh 9 . Another study by Rahman H (2012) 10 showed a significant difference (M:F=2:1) with higher male preponderance . It is found that the incidence of DM rose with the increase of age and declined sharply after the age of 50 years. All findings consistent with result of other studies. In a systematic review of randomized controlled trials (RCTs) shows that all DPP-4 inhibitors plus metformin were significantly more effective than metformin alone in reducing mean HbA1c from baseline and achieving a higher proportion of patients with HbA1c <7% 11 . Dipeptidylpeptidase-4 (DPP-4) inhibitors have a mechanism of action that is distinct from other oral glucose-lowering agents 12 . The DPP-4 inhibitor class of oral anti-diabetic agents selectively inhibits the DPP-4 enzyme that rapidly degrades two major incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 13, 15 .
DPP-4 inhibitors have also been shown to be efficacious and safe in combination therapy with metformin, SUs, TZDs and insulin 15 . Scheen 13 reviewed DPP-4 inhibitors in 2011, analyzing the similarities and differences among members of the DPP-4 inhibitor class of oral anti-diabetic agents, including their efficacy and safety profiles as monotherapy or in combination with metformin, a sulfonylurea (SU) and/ or a thiazolidinedione, and insulin. The review demonstrated that, although DDP-4 inhibitors produce a similar reduction in glycosylated hemoglobin (HbA1c) levels compared with other existing classes of oral glucose-lowering agents, DPP-4 inhibitors offer several clinical advantages 14 . These include negligible risk of hypoglycemia, much lower than that observed with SUs, and weight neutrality, compared with the weight gain that is generally associated with SUs and thiazolidinediones 13 .
The pharmacokinetics across the DPP-4 class of oral diabetes medications is, in general, similar with a few exceptions. The agents in this class have good oral bioavailability which remains essentially unchanged with food intake. The relatively long half-lives of sitagliptin, linagliptin and alogliptin allow for once-daily dosing. Saxagliptin and vildagliptin both have shorter half-lives but saxagliptin is still dosed once daily because of its active metabolite while vildagliptin is dosed twice daily (b.i.d.) 12 . Based on the above knowledge, the combination of DPP-4 inhibitor suggested as a promising treatment strategy for improving glycemic control while attenuating insulinrelated risks in T2D patients.
Conclusion:
A The principal finding of this study is DPP-4 inhibitors combination therapy is the best medication across the class in terms of key efficacy and safety outcomes (HbA 1c , FBS, PPG and proportion of patients achieving HbA 1c <7%). Glycaemic control would prevent microvascular and macrovascular complications of type 2 diabetes. Several categories of oral antidiabetic drugs including biguanides, sulfonylureas, meglitinides, DPP-4 (dipeptidyl peptidase-4) inhibitors are available for tretment of type 2 diabetes. Efficacies of these drugs should be monitored for clinical evaluation and for further management. Other oral agents, like metformin are less efficacious than DPP-4 inhibitors combination but have proven non-inferior to SU treatment with a favorable side-effect profile and less risk for hypoglycemia. In conclusion, our data indicate that the combination treatment of DPP-4 inhibitor is beneficial in terms of glycemic control. However, additional studies are warranted to establish the optimal approach for its application in clinical practice.
